Table 2. Overall clinical outcomes.
| Total population | Propensity-matched population | |||||
|---|---|---|---|---|---|---|
| No Statin (n = 299) | Statin (n = 756) | p value | No Statin (n = 256) | Statin (n = 256) | p value | |
| Overall MACE * | 44 (14.7%) | 125 (16.5%) | 0.47 | 32 (12.5%) | 46 (18.0%) | 0.11 |
| All-cause mortality | 12 (4.0%) | 43 (5.7%) | 0.27 | 9 (3.5%) | 13 (5.1%) | 0.51 |
| Cardiac death | 9 (3.0%) | 32 (4.2%) | 0.35 | 6 (2.3%) | 9 (3.5%) | 0.60 |
| Non-cardiac death | 3 (1.0%) | 11 (1.5%) | 0.56 | 3 (1.2%) | 4 (1.6%) | 0.99 |
| Myocardial infarction | 6 (2.0%) | 16 (2.1%) | 0.91 | 6 (2.3%) | 5 (2.0%) | 0.99 |
| Repeated Revascularization | 24 (8.0%) | 55 (7.3%) | 0.68 | 17 (6.6%) | 23 (9.0%) | 0.41 |
| TLR | 12 (4.0%) | 28 (3.7%) | 0.81 | 10 (3.9%) | 13 (5.1%) | 0.67 |
| TVR | 4 (1.3%) | 8 (1.1%) | 0.70 | 4 (1.6%) | 2 (0.8%) | 0.69 |
| CABG | 2 (0.7%) | 6 (0.8%) | 0.83 | 1 (0.4%) | 0 (0%) | 0.99 |
| Stent thrombosis | 1 (0.3%) | 7 (0.9%) | 0.32 | 1 (0.4%) | 5 (2%) | 0.22 |
*Composed of all-cause mortality, myocardial infarction and repeated revascularization.
CABG, coronary artery bypass grafting; CI, confidence interval; HR, hazard ratio; MACE, major adverse cardiovascular event; TLR, target-lesion revascularization; TVR, target-vessel revascularization